Adam Friedman, MD, PhD
Founder and President
Leap Oncology
Adam Friedman, MD, PhD, is a physician, scientist, and entrepreneur. He was a co-founder and Director of Corporate Development at Raze Therapeutics, a next-generation cancer metabolism therapeutic discovery company, launched while an Entrepreneur-in-Residence at Atlas Venture. While at Atlas, he helped to launch biotechnology companies exploring new areas of biology to alleviate human disease. He received his AB in molecular biology from Princeton University and completed the MD/PhD degree program at Harvard Medical School in the Harvard-MIT Division of Health Sciences and Technology, with graduate work in genetics and cell biology. A licensed Massachusetts physician, Dr. Friedman received training in pediatrics at Boston Children’s Hospital. He has authored multiple peer-reviewed publications in the fields of systems biology, cell signaling, genetics, and cancer biology, with an emphasis on novel models for predicting patient responses to cancer therapy.